The Formulation and Evaluation of Topical Berberine-Hydrochloride Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Formulation and Evaluation of Topical Berberine-Hydrochloride Products
The authors sought to prepare a topical formulation of berberine hydrochloride for the effective and controlled management of inflammation and skin infections.


Pharmaceutical Technology
Volume 34, Issue 1, pp. 60-69

Formulation M5 (12.5% w/w menthol), prepared using Apifil, showed the highest in vitro permeability of BRB, hence this formulation was selected for skin-irritation and anti-inflammatory studies.


Table IV: Skin irritation scores following topical berberine-hydrochloride cream application.
Skin-irritation test. The skin-irritation test of Formulation M5 resulted in a score of less than 2 (see Table IV). Compounds that have scores of 2 or less are considered to be nonirritants (21). Hence, both types of topical cream formulations may be categorized as nonirritants.


Table V: Anti-inflammatory activity of different topical gel formulations of berberine hydrochloride.
Anti-inflammatory studies. The results of anti-inflammatory activity studies after topical application are reported in Table V. For the control formulation, the paw volume increases arithmetically with time. Formulation M5 and the standard diclofenac gel formulation showed better reduction in paw-volume measurement than did the control formulation. Statistical analysis showed that the edema inhibition of Formulation M5 and the standard diclofenac gel formulation were much better than that of the control group (P < 0.05). However, there was no statistical difference between the anti-inflammatory effects of formulation M5 or the standard diclofenac gel (P >0.05).

Conclusion

Topical applications have a great potential as an effective and safe way to administer BRB for local antimicrobial and anti-inflamatory effects. An antimicrobial study of a prepared cream formulation of BRB indicated good antibacterial activity against S. aureus and antifungal effect against C. albicans. An in vitro permeation study using rat epidermal membranes and anti-inflammatroy studies by the carrageenan-induced rat-paw edema method showed that menthol enhanced the transdermal absorption of BRB formulations based on aqueous cream BP. The topical-cream formulations of BRB developed in this study have great utility and are a viable option for the effective and controlled management of inflammation and skin infections caused by S. aureus and C. albicans.

Nikunjana A. Patel* is an assistant professor in the department of pharmacognosy, Natvar J. Patel is a principal, Rakesh P. Patel is an associate professor, and Rakesh K. Patel is a professor, all at S.K. Patel College of Pharmaceutical Education and Research, Ganpat University, Kherva, 382711 Mehsana, Gujarat, India, fax +91 2762 286082,
.

*To whom all correspondence should be addressed.

Submitted: Feb. 20, 2009. Accepted: Mar. 23, 2009.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here